30 closest matches · ranked by relevance
Hypoparathyroidism
Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)
Osteoporosis
Primary: Number of Participants With Adverse Events — 6; 2; 3; 5 Participants
Growth and Development
Primary: Change From Baseline in Serum Cross Linking C-telopeptide of Type 1 Collagen (s-CTX-1) at 6 Months — 0.4440; 0.4410; 0.2828; 0.3245 Micrograms per litres (mcg/L)…
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Osteopenia
Primary: Number of Participants With Adverse Events — 6; 4; 3; 6 Participants
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
Healthy
Primary: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA)…
Postmenopause · Hypertension · Pre-Hypertension
Primary: Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population — -1.03…
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: Number of Participants With Treatment Emergent Adverse Events — 11; 10 Participants
Healthy
Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change
Japanese Premenopausal Healthy Adult Women
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-385 — 23.44; 29.05; 10.94 nanogram per milliliter (ng/mL) — p=0.659
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Postmenopausal Osteoporosis (PMO)
Primary: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine — 0.9; 8.4; 13.3; 16.9 percent change — p=< 0.0001
Infertility · Ovulation Induction
Primary: Percentage of Participants With Ovulation — 79.1; 82.6 percentage of participants
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants
Menopause · Osteoporosis · Osteopenia
Primary: Change From Baseline in Bone Mineral Density — 1.146; 1.132 g/cm2
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Osteoporosis
Primary: Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo — 3.6; 10.3; 7.2 Vertebral fractures — p=0.0001
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — .46; 5.71; 6.73; 7.45 Percent Change from Baseline — p=<0.0001
Menopause · Obesity
Primary: Brown Adipose Tissue Volume — 53.1; 20.6 mL
Bone Health in Perimenopausal Women
Primary: Changes in DPD(Deoxypyridinoline) — 7.1; 6.4; 6.2; 5.6 nanoMolar DPD per milliMolar creatine
Phase 1 Pharmacodynamic Study
Primary: Pharmacodynamic Effect of Oral Calcitonin — 37.5; 100; 41.2; 44.4 percentage of time-matched placebo respo
Aging
Primary: Tissue Saturation Index (TSI) - Active Leg Muscle — -5.1; -3.1; -8.7; -6.3 % Total Labile Signal
Atherosclerosis
Primary: Progression of Subclinical Atherosclerosis — 4.77; 5.68 um/year — p=0.35
Postmenopause
Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…
Osteoporosis
Primary: Number of Participants With Serum Calcium Level Over 11.0 Milligrams Per Deciliter (mg/dL) — 0; 0 participants
Female Sexual Dysfunction
Primary: Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles — 223.981; 328.002; 834.391; 553.325 ng*h/dL